<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03330184</url>
  </required_header>
  <id_info>
    <org_study_id>2013KTZB</org_study_id>
    <nct_id>NCT03330184</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety of Berberine Hydrochloride and Bifidobacterium in People With Abnormal Glucose Level</brief_title>
  <official_title>Effectiveness and Safety of Berberine Hydrochloride and Bifidobacterium in People With Abnormal Glucose Level: an Multicenter, Randomized, Double-blinded, Placebo-controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shaanxi Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the beneficial effects of Bifidobacterium and Berberine
      Hydrochloride on lowering glucose and delaying progress to diabetes in patients with
      prediabetes and to detect the potential mechanism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gut microbiota may play an important role in patients with prediabetes. Berberine, which is
      usually used as an antibiotic drug, has been reported a potential glucose-lowering effect in
      vitro and in vivo studies. Bifidobacterium, as a familiar probiotics, can modulate gut
      microbiota and improve glucose and lipid metabolism in animal experiments. Therefore, the aim
      of this study is to assess the beneficial effects of Bifidobacterium and Berberine
      Hydrochloride on lowering glucose and delaying progress to diabetes in patients with
      prediabetes and to detect the potential mechanism.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in fasting blood glucose between baseline to week 16</measure>
    <time_frame>baseline and week 16</time_frame>
    <description>fasting blood glucose are measured at baseline and week 16</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 2-hour postprandial blood glucose between baseline to week 16</measure>
    <time_frame>baseline and week 16</time_frame>
    <description>2-hour postprandial blood glucose are measured at baseline and week 16 during Oral Glucose Tolerance Test(OGTT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbiome composition</measure>
    <time_frame>baseline and week 16</time_frame>
    <description>faecal bacterial composition determined from microbiological cultures and deep metagenomic next-generation sequencing of bacterial DNA in feces</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Berberine Hydrochloride</condition>
  <arm_group>
    <arm_group_label>Berberine Hydrochloride group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2/day, 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bifidobacterium group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2/day, 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Berberine Hydrochloride and Bifidobacterium group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2/day, 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>bifidobacterium mimetic capsules berberine mimetic tablets,2/day, 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berberine Hydrochloride group</intervention_name>
    <arm_group_label>Berberine Hydrochloride group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bifidobacterium group</intervention_name>
    <arm_group_label>Bifidobacterium group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berberine Hydrochloride and Bifidobacterium group</intervention_name>
    <arm_group_label>Berberine Hydrochloride and Bifidobacterium group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent obtained before any trial-related activities.

          -  Male or female between 18 and 70 years of age.

          -  19≤Body mass index(BMI)≤30kg/m2.

          -  No participate in any clinical trial at least 3 months.

          -  Diagnosed impaired fasting glucose(IFG) and impaired glucose tolerance(IGT) or
             Diabetes.

          -  In visit 1, 5.60mmol/L≤Fasting blood glucose(FBG)&lt;8.0mmol/L; in visit 2,
             6.1≤FPG&lt;8.0mmol/L or 7.8≤2-hour postprandial blood glucose(2h-PPG) &lt;17mmol/L.

          -  Females in child-bearing period should be given birth control.

          -  No severe disease about heart, lung and kidney.

          -  Ability and willingness to adhere to the protocol including performance of
             self-monitored blood glucose (SMBG) profiles according to the protocol.

          -  Subject is likely to comply with the Investigators instruction.

        Exclusion Criteria:

          -  Type 1 diabetes mellitus.

          -  Diabetes patients with already be treated or not be treated but FBG ≥8mmol/L or 2h-PPG
             ≥ 17mmol/L.

          -  Females of childbearing potential who are pregnant，breastfeeding or intend to become
             pregnant or are not using adequate contraceptive methods.

          -  Impaired liver function, defined as Aspartate aminotransferase(AST) or Alanine
             transaminase(ALT)&gt; 2 times upper limit of normal .

          -  Impaired renal function, defined as serum-creatinine≥133μmol/L.

          -  Uncontrolled treated/untreated severe hypertension (systolic blood pressure≥160mmHg
             and /or diastolic blood pressure≥95mmHg).

          -  Chronic gastrointestinal diseases.

          -  Cancer and medical history of cancer (except basal cell skin cancer or squamous cell
             skin cancer).

          -  Any clinically significant disease or disorder, which in the Investigator's opinion
             could interfere with the results of the trial.

          -  Mental incapacity, psychiatric disorder, unwillingness or language barriers precluding
             adequate understanding or co-operation, including subjects not able to read and write.

          -  Known or suspected hypersensitivity to trial products or related products.

          -  Known or suspected abuse of alcohol, narcotics or illicit drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qiuhe Ph.D. Ji, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Endocrinology,Xi jing Hospital,Fourth Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qiuhe Ph.D. Ji, M.D.</last_name>
    <email>qiuheji@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jie Ming, M.D.</last_name>
    <phone>(86)18629301253</phone>
    <email>mingjie1207@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an,</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BingYin Shi, Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>BingYin Shi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuan Xie, Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Xuan Xie, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shaanxi Provincial People's Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710068</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YangWei Wang, Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>YangWei Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>October 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bifidobacterium</keyword>
  <keyword>People With Abnormal Glucose Level</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

